<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Panitumumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Panitumumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Panitumumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11820" href="/d/html/11820.html" rel="external">see "Panitumumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709195"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Dermatologic toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dermatologic toxicities occurred in 90% of patients and were severe (National Cancer Institute Common Toxicity Criteria [NCI-CTC] grade 3 and higher) in 15% of patients receiving panitumumab monotherapy.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F3343189"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vectibix</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868825"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Vectibix</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F3343193"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F3343261"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Establish <i>RAS</i> mutation status (to confirm <i>RAS</i> wild-type) prior to treatment initiation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="93843275-d7d5-40c2-9b77-875e6c906074">Colorectal cancer, metastatic, <i>RAS</i> wild-type</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer, metastatic, <i>RAS</i> wild-type:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single agent therapy: </i>
<b>IV: </b>6 mg/kg every 14 days; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17470858']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17470858'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with CAPOX (capecitabine and oxaliplatin; off-label combination): </i>
<b>IV: </b>9 mg/kg every 21 days for at least 6 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29855806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29855806'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with FOLFOX (fluorouracil, leucovorin, and oxaliplatin): </i>
<b>IV: </b>6 mg/kg every 14 days; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24024839','lexi-content-ref-20921465']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24024839','lexi-content-ref-20921465'])">Ref</a></span>).<b> Note: </b>Data from a phase 3 randomized, multicenter trial showed significantly improved overall survival in patients with previously untreated <i>RAS</i> wild-type and left-sided metastatic colorectal cancer who received panitumumab in combination with mFOLFOX6 versus bevacizumab in combination with mFOLFOX6 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Yoshino.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Yoshino.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with FOLFIRI (fluorouracil, leucovorin, and irinotecan; off-label combination):</i>
<b> IV: </b>6 mg/kg every 14 days; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20921462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20921462'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan; off-label combination): </i>
<b>IV: </b>6 mg/kg every 14 days until disease progression or resection for up to a maximum of 12 preoperative cycles; after resection, patients received the same regimen as adjuvant therapy for a total of 12 perioperative cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31609637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31609637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>As maintenance therapy (in combination with fluorouracil and leucovorin) following 6 cycles of FOLFOX plus panitumumab; off-label combination): </i>
<b>IV: </b>6 mg/kg every 14 days; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34533973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34533973'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e05c3ab-ee62-41af-b77f-0ed8ae089dcb">Cutaneous squamous cell carcinoma, unresectable, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous squamous cell carcinoma, unresectable, advanced or metastatic (off-label use): IV: </b>6 mg/kg IV every 14 days until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25091317','lexi-content-ref-32294281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25091317','lexi-content-ref-32294281'])">Ref</a></span>) or for a maximum of 9 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25091317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25091317'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991978"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, no need for dosage adjustment is expected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989111"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling. The following adjustments have been recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment: No dosage adjustment is needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: No need for dosage adjustment is expected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block doo drugH1Div" id="F57498304"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2</sup></i>
<i>:</i> The dosing in the FDA-approved prescribing information should be followed in all patients, regardless of obesity status. If a patient with a BMI ≥30 kg/m<sup>2 </sup>experiences high-grade toxicity from systemic anticancer therapy, the same dosage modification recommendations should be followed for all patients, regardless of obesity status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F3343265"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Electrolyte depletion: Replete as clinically appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">Infusion reactions:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate (grade 1 or 2): Reduce the infusion rate by 50% for the duration of infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe (grade 3 or 4): Stop infusion; consider permanent discontinuation (depending on severity or persistence of reaction).</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic or soft tissue toxicity:</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 toxicity (first occurrence): Withhold 1 to 2 doses; if reaction improves to &lt;grade 3, resume therapy at initial dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 toxicity (second occurrence): Withhold 1 to 2 doses; if reaction improves to &lt;grade 3, resume therapy at 80% of initial dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 toxicity (third occurrence): Withhold 1 to 2 doses; if reaction improves to &lt;grade 3, resume therapy at 60% of initial dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 toxicity (fourth occurrence), grade 3 toxicity that does not recover to &lt;grade 3 after withholding 1 or 2 doses, or grade 4 toxicity: Permanently discontinue.</p>
<p style="text-indent:-2em;margin-left:2em;">Ocular toxicity (acute or worsening keratitis, ulcerative keratitis, or corneal perforation): Interrupt or discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Pulmonary toxicity:</p>
<p style="text-indent:-2em;margin-left:4em;">Acute onset or worsening pulmonary symptoms: Interrupt treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Interstitial lung disease: Permanently discontinue treatment.</p></div>
<div class="block doe drugH1Div" id="F3343262"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F3343245"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (14%), acneiform eruption (57%), erythema of skin (66%), exfoliative dermatitis (18%), paronychia (25%), pruritus (58%), skin fissure (20%), skin rash (22%), skin toxicity (90%; severe dermatological reaction: 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (23%; grade 3/4: &lt;1%), diarrhea (21%; grades 3/4: 2%), vomiting (19%; grade 3/4: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Ocular toxicity (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (15%), dyspnea (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pulmonary embolism (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal ulcer (6%), desquamation (9%), nail disease (10%), papular rash (2%), pustular rash (4%), xeroderma (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (3%), hypomagnesemia (grades 3/4: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Mucosal swelling (inflammation: 7%), stomatitis (7%), xerostomia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (≤5%; neutralizing: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal eyelash growth (6%), conjunctivitis (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (4%), interstitial pulmonary disease (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion related reaction (3% to 4%; severe infusion reaction: ≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Respiratory: Pulmonary fibrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous skin disease (mucocutaneous), skin necrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal perforation, corneal ulcer, keratitis (including ulcerative)</p></div>
<div class="block coi drugH1Div" id="F3343241"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> History of severe or life-threatening hypersensitivity reactions to panitumumab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F3343242"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Dermatologic toxicities have been reported in most patients receiving single agent panitumumab; severe (≥ grade 3) reactions have occurred; manifestations included dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures. Severe skin toxicities may be complicated by infection, sepsis, necrotizing fasciitis, or abscesses. The median time to development of skin (or ocular) toxicity was 12 days, with resolution ~14 weeks. The severity of dermatologic toxicity is predictive for response; grades 2 to 4 skin toxicity correlates with improved progression free survival and overall survival, compared to grade 1 skin toxicity (Peeters 2009; Van Cutsem 2007). Rare cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported; bullous mucocutaneous disease (life-threatening/fatal) have been observed. Patients should minimize sunlight exposure and wear sunscreen and protective clothing/hat; sunlight may exacerbate skin reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diarrhea: May cause diarrhea; the incidence and severity of chemotherapy-induced diarrhea is increased with combination chemotherapy. Severe diarrhea and dehydration (which may lead to acute renal failure) has been observed with panitumumab in combination with chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte depletion: Magnesium and/or calcium depletion may occur during treatment; may be delayed. Hypomagnesemia occurred during and for up to 8 weeks after completion of panitumumab treatment. Hypokalemia has also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Severe infusion reactions (bronchospasm, dyspnea, fever, chills, and hypotension) have been reported in ~1% of patients; fatal infusion reactions have been reported with postmarketing surveillance. Appropriate medical support for the management of infusion reactions should be readily available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular toxicity: Keratitis, ulcerative keratitis, and corneal perforation have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Pulmonary fibrosis and interstitial lung disease have been observed (rarely) in clinical trials; fatalities have been reported. Patients with a history of or evidence of interstitial pneumonitis or pulmonary fibrosis were excluded from most clinical trials; consider the benefits of therapy versus the risk of pulmonary complications in such patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Colorectal cancer and <i>RAS</i> mutation status: Confirm absence of <i>RAS</i> mutation prior to treatment; patients with codons 12 and 13 (exon 2), codons 59 and 61 (exon 3), or codons 117 and 146 (exon 4) <i>RAS</i> (<i>KRAS</i> or <i>NRAS</i>) mutations are unlikely to benefit from EGFR inhibitor therapy. The American Society of Clinical Oncology (ASCO) provisional clinical opinion update, as well as a guideline for molecular biomarkers for the evaluation of colorectal cancer, recommend that all patients with metastatic colorectal cancer who are candidates for anti-EGFR therapy should be tested (in a certified lab) for mutations in both <i>KRAS</i> and <i>NRAS</i> exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146); anti-EGFR monoclonal antibody therapy should only be considered in patients whose tumors lack mutations after extended <i>RAS</i> testing (ASCO [Allegra 2016]; ASCP/CAP/AMP/ASCO [Sepulveda 2017]). Information on tests approved for detection of RAS mutation is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2FCompanionDiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IPc%2BkYYsON95PtA1EteUbfjUoJYJ%2BuveJw2PtFUTXMkK&amp;TOPIC_ID=10336" target="_blank">www.fda.gov/CompanionDiagnostics</a>. Panitumumab is also reported to be ineffective in patients with BRAF V600E mutation (Di Nicolantonio 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bevacizumab and combination chemotherapy: In a study of bevacizumab with combination chemotherapy ± panitumumab, the use of panitumumab resulted in decreased progression-free and overall survival and significantly increased toxicity compared to regimens without panitumumab (Hecht 2009). Toxicities included rash/acneiform dermatitis, diarrhea/dehydration, electrolyte disturbances, mucositis/stomatitis, and an increased incidence of pulmonary embolism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients &gt;65 years of age receiving panitumumab plus FOLFOX experienced a higher incidence of serious adverse events including severe diarrhea.</p></div>
<div class="block foc drugH1Div" id="F3343274"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vectibix: 100 mg/5 mL (5 mL); 400 mg/20 mL (20 mL)</p></div>
<div class="block geq drugH1Div" id="F3343191"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F5685563"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vectibix Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $395.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg/20 mL (per mL): $395.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868826"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vectibix: 100 mg/5 mL (5 mL); 400 mg/20 mL (20 mL)</p></div>
<div class="block adm drugH1Div" id="F3343266"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV infusion only; do not administer IV push or as a bolus. Administer via infusion pump through a low protein-binding 0.2 or 0.22 micrometer in-line filter. Doses ≤1,000 mg, infuse over 1 hour; if first infusion is tolerated, subsequent doses may be administered over 30 to 60 minutes. Doses &gt;1,000 mg, infuse over 90 minutes. Flush line with NS before and after infusion; do not mix or administer with other medications. Reduce infusion rate by 50% for mild to moderate infusion reactions (grades 1 and 2); stop infusion for severe infusion reactions (grades 3 and 4) and consider permanent discontinuation. Appropriate medical support for the management of infusion reactions should be readily available.</p></div>
<div class="block use drugH1Div" id="F3343195"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer, metastatic: </b>Treatment of wild-type <i>RAS</i> (defined as wild-type in both <i>KRAS</i> and <i>NRAS</i> as determined by an approved test) metastatic colorectal cancer (mCRC), either as first-line therapy in combination with FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or as a single agent following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Panitumumab is not indicated for the treatment of patients with <i>RAS</i>-mutant mCRC or for whom <i>RAS</i> mutation status is unknown.</p></div>
<div class="block off-label drugH1Div" id="F25469580"><span class="drugH1">Use: Off-Label: Adult</span><p>Colorectal cancer, metastatic, KRAS wild-type (in combination with other chemotherapy agents); Cutaneous squamous cell carcinoma, unresectable, advanced or metastatic</p></div>
<div class="block mst drugH1Div" id="F14471958"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Panitumumab may be confused with pembrolizumab, pertuzumab, polatuzumab vedotin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299817"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6222127"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49309064"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients who could become pregnant should use effective contraception during treatment and for 2 months after the dose of panitumumab.</p></div>
<div class="block pri drugH1Div" id="F3343197"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on animal reproduction studies and on the mechanism of action, panitumumab may cause fetal harm if administered during pregnancy. Panitumumab is a humanized monoclonal antibody (IgG<sub>2</sub>). Potential placental transfer of human IgG is dependent upon the IgG subclass and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p></div>
<div class="block brc drugH1Div" id="F3343200"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if panitumumab is present in breast milk. Panitumumab is an IgG monoclonal antibody and maternal IgG immunoglobulins are excreted in breast milk; however, breast milk antibodies are not expected to enter neonatal and infant circulation in substantial amounts. Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends patients not breastfeed during therapy and for 2 months after the final panitumumab dose.</p></div>
<div class="block mop drugH1Div" id="F3343269"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>RAS</i> genotyping of tumor tissue to confirm <i>RAS</i> wild-type (prior to treatment initiation). Monitor serum electrolytes, including magnesium and calcium (periodically during and for at least 8 weeks after therapy), and potassium. Monitor vital signs and temperature before, during, and after infusion. Monitor all dermatologic toxicities for development of inflammation or infection, for evidence of ocular toxicity (eg, keratitis, ulcerative keratitis, or corneal perforation), and for acute onset or worsening pulmonary symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F3343255"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Panitumumab is a recombinant human IgG2 monoclonal antibody which binds specifically to the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands. Binding to the EGFR blocks phosphorylation and activation of intracellular tyrosine kinases, resulting in inhibition of cell survival, growth, proliferation, and transformation. EGFR signal transduction may result in <i>KRAS</i> and <i>NRAS</i> wild-type activation; cells with <i>RAS</i> mutations appear to be unaffected by EGFR inhibition.</p></div>
<div class="block phk drugH1Div" id="F3343257"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Half-life elimination: ~7.5 days (range: 4 to 11 days)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6875345"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Vectibix</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26438111">
<a name="26438111"></a>Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. <i>J Clin Oncol.</i> 2016;34(2):179-185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/26438111/pubmed" id="26438111" target="_blank">26438111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18316791">
<a name="18316791"></a>Amado RG, Wolf M, Peeters M, et al. Wild-Type KRAS is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. <i>J Clin Oncol</i>. 2008;26(10):1626-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/18316791/pubmed" id="18316791" target="_blank">18316791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19001320">
<a name="19001320"></a>Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. <i>J Clin Oncol</i>. 2008;26(35):5705-5712.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/19001320/pubmed" id="19001320" target="_blank">19001320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24024839">
<a name="24024839"></a>Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. <i>N Engl J Med</i>. 2013;369(11):1023-1034.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/24024839/pubmed" id="24024839" target="_blank">24024839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20921465">
<a name="20921465"></a>Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. <i>J Clin Oncol</i>. 2010;28(31):4697-4705.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/20921465/pubmed" id="20921465" target="_blank">20921465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25091317">
<a name="25091317"></a>Foote MC, McGrath M, Guminski A, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. <i>Ann Oncol.</i> 2014;25(10):2047-2052. doi:10.1093/annonc/mdu368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/25091317/pubmed" id="25091317" target="_blank">25091317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19114685">
<a name="19114685"></a>Hecht JR, Mitchell E, Chidiac T, et al. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. <i>J Clin Oncol</i>. 2009;27(5):672-680.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/19114685/pubmed" id="19114685" target="_blank">19114685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32294281">
<a name="32294281"></a>Hourbeigt K, Ehret M, Visseaux L, et al. Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma. <i>J Eur Acad Dermatol Venereol.</i> 2020;34(12):2789-2794. doi:10.1111/jdv.16465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/32294281/pubmed" id="32294281" target="_blank">32294281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29331386">
<a name="29331386"></a>Kim JYS, Kozlow JH, Mittal B, Moyer J, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. <i>J Am Acad Dermatol</i>. 2018;78(3):560-578. doi:10.1016/j.jaad.2017.10.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/29331386/pubmed" id="29331386" target="_blank">29331386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34533973">
<a name="34533973"></a>Modest DP, Karthaus M, Fruehauf S, et al. Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: the randomized PANAMA trial (AIO KRK 0212). <i>J Clin Oncol.</i> 2022;40(1):72-82. doi:10.1200/JCO.21.01332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/34533973/pubmed" id="34533973" target="_blank">34533973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31609637">
<a name="31609637"></a>Modest DP, Martens UM, Riera-Knorrenschild J, et al. FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109). <i>J Clin Oncol.</i> 2019;37(35):3401-3411. doi:10.1200/JCO.19.01340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/31609637/pubmed" id="31609637" target="_blank">31609637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29855806">
<a name="29855806"></a>Papaxoinis G, Kotoula V, Giannoulatou E, et al. Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. <i>Med Oncol</i>. 2018;35(7):101. doi:10.1007/s12032-018-1160-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/29855806/pubmed" id="29855806" target="_blank">29855806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20921462">
<a name="20921462"></a>Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. <i>J Clin Oncol</i>. 2010;28(31):4706-4713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/20921462/pubmed" id="20921462" target="_blank">20921462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19189371">
<a name="19189371"></a>Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. <i>Cancer</i>. 2009;115(7):1544-1554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/19189371/pubmed" id="19189371" target="_blank">19189371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16012181">
<a name="16012181"></a>Segaert S and Van Cutsem E. Clinical Signs, Pathophysiology and Management of Skin Toxicity During Therapy with Epidermal Growth Factor Receptor Inhibitors. <i>Ann Oncol</i>. 2005;16(9):1425-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/16012181/pubmed" id="16012181" target="_blank">16012181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28165299">
<a name="28165299"></a>Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. <i>J Clin Oncol.</i> 2017;35(13):1453-1486. doi:10.1200/JCO.2016.71.9807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/28165299/pubmed" id="28165299" target="_blank">28165299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17470858">
<a name="17470858"></a>Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III Trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. <i>J Clin Oncol</i>. 2007;25(13):1658-1664.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panitumumab-drug-information/abstract-text/17470858/pubmed" id="17470858" target="_blank">17470858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vectibix.1">
<a name="Vectibix.1"></a>Vectibix (panitumumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vectibix.2">
<a name="Vectibix.2"></a>Vectibix (panitumumab) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; March 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yoshino.1">
<a name="Yoshino.1"></a>Yoshino T, Watanabe J, Shitara K, et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial. 2022 ASCO Annual Meeting abstract. <i>J Clin Oncol</i>. 2022;40(17)(suppl):LBA1. doi:10.1200/JCO.2022.40.17_suppl.LBA1</div>
</li></ol></div><div id="topicVersionRevision">Topic 10336 Version 197.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
